Robert E. Sobol

Girls Incorporated — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index2.3kcitations58works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(22), Cancer Research and Treatments(14), Monoclonal and Polyclonal Antibodies Research(12), CAR-T cell therapy research(11), Immunotherapy and Immune Responses(9)

Publications58 total

Tumor suppressor immune gene therapy to reverse immunotherapy resistance
Cancer Gene Therapy·2021· 29 citedOpen Access
Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
Frontiers in Oncology·2021· 25 citedOpen Access
Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
2021· 1 citedOpen Access
Tumor Suppressor Immune Gene Therapy to Reverse Immunotherapy Resistance
2021· 4 citedOpen Access
Reversing immune checkpoint inhibitor resistance with adenoviral IL-24 and p53 tumor suppressor immune gene therapy.
Journal of Clinical Oncology·2018· 7 cited
Effect of adenoviral p53 (Ad-p53) tumor suppressor immune gene therapy on checkpoint inhibitor resistance and abscopal therapeutic efficacy.
Journal of Clinical Oncology·2017· 5 cited
Tp53 Gene Therapy for Cancer Treatment and Prevention
2012· 6 cited
The Journal of Cancer Gene and Cellular Therapies
Cancer Gene Therapy·2010· 1 citedOpen Access
Biomarkers Predict<i>p53</i>Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
Clinical Cancer Research·2009· 94 cited
Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN)
Journal of Clinical Oncology·2007· 3 cited
<i>p53</i> therapy in a patient with Li-Fraumeni syndrome
Molecular Cancer Therapeutics·2007· 54 cited
Abnormal overexpression of p53 is a predictive molecular biomarker of Advexin (adenoviral p53) efficacy in recurrent squamous cell carcinoma of the head and neck (SCCHN)
Clinical Cancer Research·2006
The rationale for prophylactic cancer vaccines and need for a paradigm shift
Cancer Gene Therapy·2006· 15 cited
943. Prognostic Determinants Associated with Efficacy of Adenoviral p53 Gene Therapy in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck
Molecular Therapy·2006· 2 cited
Improved cancer vaccines through gene transfer
Cancer Gene Therapy·2005Open Access
Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine
Clinical & Experimental Immunology·2002· 19 citedOpen Access
The Unwritten Chapters Gene Therapy of Cancer, 2nd ed.
Molecular Therapy·2002Open Access
The response of human breast tumour cell lines with altered polymerase beta levels to cisplatin and radiation.
PubMed·2001· 18 cited
Immunotherapy of Advanced Malignancy by Direct Gene Transfer of an Interleukin-2 DNA/DMRIE/DOPE Lipid Complex: Phase I/II Experience
Journal of Clinical Oncology·1999· 99 cited
Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study.
PubMed·1999· 69 cited
page 1 of 3Next →

Frequent Co-authors

Ivor Royston(23), Daniel L. Shawler(13), Habib Fakhrai(11), Kerstin B. Menander(10), John Nemunaitis(9), Sunil Chada(9), Ruth A. Gjerset(7), Dan Mercola(6), Robert O. Dillman(6), Richard M. Bartholomew(6), Dora Wiederhold(6), Clara D. Bloomfield(5), Oliver Dorigo(5), Daniel P. Gold(5), Oliver Dorigo(4), Heli Collins(4), Gary L. Clayman(4), Robert W. Astarita(4), Dennis J. Carlo(4), Beatha Sellman(4)